News

The National Institute of Health and Care Excellence (NICE), an arm of the United Kingdom’s public health system, favors use of the oral cannabidiol solution Epidyolex as an add-on to clobazam to treat seizures associated with Lennox Gastaut syndrome (LGS) and Dravet syndrome in patients in…

Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…

Onfi (clobazam), as an adjunct seizure treatment for Lennox-Gastaut syndrome (LGS), significantly reduced the number of weekly drop seizures and its effects were maintained in some patients for up to five years, a study summarizing clinical evidence reports.  The study, “…

Zogenix has enrolled the last patient in a Phase 3 clinical trial evaluating its lead investigational candidate Fintepla (ZX008) as an add-on therapy for seizures associated with Lennox‑Gastaut syndrome (LGS), the company has announced. The study’s top-line data are expected in the first quarter of next year. Fintepla,…

Long-term treatment with the investigational oral therapy soticlestat (OV935/TAK-935) can reduce the median seizure frequency by up to 90% in adults with Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies (DEE), according to data from the ENDYMION Phase 2 trial. Topline results are expected in the…

The European Commission has approved Epidyolex (cannabidiol, CBD) as an add-on therapy to clobazam to treat seizures associated with Lennox‑Gastaut syndrome (LGS) and Dravet syndrome in patients 2 and older. Epidyolex — which is the first CBD product to be approved by the European Medicines Agency (EMA)…